US FDA Approves Expanded Indication for AbbVie’s MAVYRET^® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

AbbVie announced that the US FDA approved a label expansion for MAVYRET^®, an oral pangenotypic direct acting antiviral therapy. It is now approved for the treatment of adults and pediatric patients three years and older with acute or chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis.